142 related articles for article (PubMed ID: 36830885)
21. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.
López-Medrano F; Pérez-Jacoiste Asín MA; Fernández-Ruiz M; Carretero O; Lalueza A; Maestro de la Calle G; Caro JM; de la Calle C; Catalán M; García-García R; Martínez-López J; Origüen J; Ripoll M; San Juan R; Trujillo H; Sevillano Á; Gutiérrez E; de Miguel B; Aguilar F; Gómez C; Silva JT; García-Ruiz de Morales D; Saro-Buendía M; Marrero-Sánchez Á; Chiara-Graciani G; Bueno H; Paz-Artal E; Lumbreras C; Pablos JL; Aguado JM;
Int J Infect Dis; 2021 Apr; 105():487-494. PubMed ID: 33647515
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
23. A single-center experience in use of tocilizumab in COVID-19 pneumonia in India.
Joshi A; Kumar M K; Kumar A; Nair RK; Singh J; Chakrabarti R; Kapoor R
Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S296-S304. PubMed ID: 34334897
[TBL] [Abstract][Full Text] [Related]
24. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
25. Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching.
Güçlü ÖA; Önal U; Akalın H; Öztürk NAA; Belik HÖ; Demirdöğen E; Dilektaşlı AG; Kazak E; Ocakoğlu G; Sağlık İ; Coşkun F; Ediger D; Heper Y; Ursavaş A; Yılmaz E; Uzaslan E; Karadağ M
Adv Clin Exp Med; 2022 Nov; 31(11):1197-1206. PubMed ID: 35951629
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.
Gholinataj Jelodar M; Rafieian S; Saghafi F; Hadad Zedegan N; Birjandi B; Rafieian S; Allah Dini A; Dehghanpour H; Khalaj F; Zare S; Dehghan Chenari H; Hajimaghsoudi M; Mojtaba Sohrevardi S; Mirzaei S; Jamialahmadi T; Atkin SL; Sahebkar A
Int Immunopharmacol; 2023 Feb; 115():109623. PubMed ID: 36577157
[TBL] [Abstract][Full Text] [Related]
27. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
Colaneri M; Bogliolo L; Valsecchi P; Sacchi P; Zuccaro V; Brandolino F; Montecucco C; Mojoli F; Giusti EM; Bruno R; The Covid Irccs San Matteo Pavia Task Force
Microorganisms; 2020 May; 8(5):. PubMed ID: 32397399
[No Abstract] [Full Text] [Related]
29. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
30. Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study.
Radulescu A; Istrate A; Muntean M
Int J Infect Dis; 2022 Apr; 117():1-7. PubMed ID: 35093528
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study.
Zarębska-Michaluk D; Jaroszewicz J; Rogalska M; Martonik D; Pabjan P; Berkan-Kawińska A; Bolewska B; Oczko-Grzesik B; Kozielewicz D; Tudrujek-Zdunek M; Kowalska J; Moniuszko-Malinowska A; Kłos K; Rorat M; Leszczyński P; Piekarska A; Polańska J; Flisiak R
J Inflamm Res; 2021; 14():3359-3366. PubMed ID: 34295173
[TBL] [Abstract][Full Text] [Related]
32. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
33. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
Antony SJ; Davis MA; Davis MG; Almaghlouth NK; Guevara R; Omar F; Del Rey F; Hassan A; Arian MU; Antony N; Prakash BV
J Med Virol; 2021 Jan; 93(1):491-498. PubMed ID: 32644254
[TBL] [Abstract][Full Text] [Related]
34. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.
Hassan M; Syed F; Zafar M; Iqbal M; Khan NU; Mushtaq HF; Badshah M
Cureus; 2021 Dec; 13(12):e20219. PubMed ID: 35004038
[TBL] [Abstract][Full Text] [Related]
36. Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone.
Belhassen-García M; Sánchez-Puente A; Dorado-Díaz PI; López-Bernús A; Sampedro-Gómez J; Azibeiro-Melchor R; Marcano-Millán E; Rodríguez-Alonso B; Sánchez-Barrado ME; Hernández-García I; Madruga I; Hernández-Pérez G; Carbonell C; García-Aparicio J; Burgos L; López-Sánchez E; Reina C; Ramón AM; Cestero-Ramírez L; Boumhir F; Encinas-Sánchez D; Sánchez-Ledesma M; Herráez J; Araoz P; Sánchez-Crespo MJ; Rodríguez-Rodríguez S; Rodríguez-Gude AE; Sánchez-Hernández MV; Borrás R; Sagredo-Meneses V; Sánchez PL; Marcos M; Martín-Oterino JÁ
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011938
[TBL] [Abstract][Full Text] [Related]
37. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results.
Berlot G; Pintacuda S; Moro E; Paluzzano G; Scamperle A; Chillemi A; Longo I; Dattola R; Roman-Pognuz E; Tomasini A
Int J Artif Organs; 2022 Jan; 45(1):75-80. PubMed ID: 33573449
[TBL] [Abstract][Full Text] [Related]
38. Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.
Altunal LN; Aydın M; Özel AS; Çam G
Infect Dis Clin Microbiol; 2022 Jun; 4(2):116-121. PubMed ID: 38633336
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study.
Siami Z; Hedayat Yaghoobi M; Karimi P
Med J Islam Repub Iran; 2023; 37():92. PubMed ID: 38021396
[TBL] [Abstract][Full Text] [Related]
40. Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19 pneumonia: Study on paired series.
Trifi A; Abdennebi C; Mehdi A; Ben Romdhane K; Blel Y; Daly F; Zakhama B; Mestiri T; Abdellatif S; Ben Lakhal S
Tunis Med; 2022 avril; 100(4):309-312. PubMed ID: 36155902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
